Intravenous drug use: The predominant risk factors for hepatitis C virus infection

Shiraz E Medical Journal

Volumn 11, Issue 4, 2010, Pages 209-218

  Fallahian, F ^a   Najafi, A ^a   Alavian, S M ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Global prevalence; Hepatitis C virus; Intravenous drug use; Transmission

Indexed keywords

ANTIRETROVIRUS AGENT; BUPRENORPHINE; EFAVIRENZ; METHADONE;

ADDICTION; ARTICLE; COMORBIDITY; DEVELOPING COUNTRY; DRUG POTENTIATION; EDUCATION PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; INTRAVENOUS DRUG ABUSE; MENTAL DISEASE; OPIATE ADDICTION; RISK FACTOR; SEROPREVALENCE; VIRUS TRANSMISSION;

EID: 77958066312     PISSN: 17351391     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Baldo V, Baldovin T, Trivello R, Floreani A. Epidemiology of HCV infection. Curr Pharm Des. 2008; 14 (17): 1646-54.
2. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007 May 7; 13 (17): 2436-41.
3. Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int. 2005 Aug; 25 (4): 696-703.
4. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med. 2005; 8: 84-90. (Pubitemid 40613753)
5. Grebely J, deVlaming S, Duncan F, Viljoen M, Conway B. Current approaches to HCV infection in current and former injection drug users. J Addict Dis. 2008; 27 (2): 25-35.
6. Shepard CW, Finelli L, Fiore AE, Bell BP. Epidemiology of hepatitis B and hepatitis B virus infection in United States children. Pediatr Infect Dis J. 2005 Sep; 24 (9): 755-60. (Pubitemid 41324881)
7. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000 Mar 11; 355 (9207): 887-91. (Pubitemid 30137669)
8. Williams I. Epidemiology of hepatitis C in the United States. Am J Med. 1999 Dec 27; 107 (6B): 2S-9S.
9. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006 May 16; 144 (10): 705-14.
10. Rhoads J. Natural history and epidemiology of hepatitis C. J Assoc Nurses AIDS Care. 2003 Sep-Oct; 14 (5 Suppl): 18S-25S.
11. Centers for Disease Control and Prevention (CDC). Use of enhanced surveillance for hepatitis C virus infection to detect a cluster among young injection-drug users-new York, November 2004-April 2007. Morb Mortal Wkly Rep. 2008; 57 (19): 517-21.
12. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: A case-control study. Journal of Gastroenterology and Hepatology. 2002; 17 (10): 1092-7. (Pubitemid 35013965)
13. Fabris P, Baldo V, Baldovin T, Bellotto E, Rassu M, Trivello R, et al. Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol. 2008 May-Jun; 42 (5): 527-32. (Pubitemid 351572246)
14. Slavenburg S, Verduyn-Lunel FM, Hermsen JT, Melchers WJ, te Morsche RH, Drenth JP. Prevalence of hepatitis C in the general population in the Netherlands. Neth J Med. 2008 Jan; 66 (1): 13-7.
15. March JC, Oviedo-Joekes E, Romero M. Factors associated with reported hepatitis C and HIV among injecting drug users in ten European cities. Enferm Infecc Microbiol Clin. 2007 Feb; 25 (2): 91-7. (Pubitemid 46363224)
16. Delarocque-Astagneau E, Pillonel J, De Valk H, Perra A, Laperche S, Desenclos JC. An incident case-control study of modes of hepatitis C virus transmission in France. Ann Epidemiol. 2007 Oct; 17 (10): 755-62. (Pubitemid 47393640)
17. Macias J, Palacios RB, Claro E, Vargas J, Vergara S, Mira JA, et al. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int. 2008 Jul; 28 (6): 781-6. (Pubitemid 351818639)
18. Attia MA. Prevalence of hepatitis B and C in Egypt and Africa. Antivir Ther. 1998; 3 (Suppl 3): 1-9.
19. Suwanwela C, Poshyachinda V. Drug abuse in Asia. Bull Narc. 1986 Jan-Jun; 38 (1-2): 41-53.
20. Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health. 2008 Oct; 122 (10): 990-1003.
21. Suwanwela C, Kanchanahuta S, Onthuam Y. Hill tribe opium addicts: a retrospective study of 1,382 patients. Bull Narc. 1979 Jan-Mar; 31 (1): 23-40. (Pubitemid 10167382)
22. Krupitsky EM, Zvartau EE, Lioznov DA, Tsoy MV, Egorova VY, Belyaeva TV, et al. Co-morbidity of infectious and addictive diseases in St. Petersburg and the Leningrad Region, Russia. Eur Addict Res. 2006; 12 (1): 12-9.
23. Bagheri Lankarani K, Saberi-Firoozi M, Nabipoor I. Reassessment of the role of hepatitis B and C viruses in postnecrotic cirrhosis and chronic hepatitis in southern Iran. Irn J Med Sci. 1999; 24: 117-21.
24. Alizadeh AHM, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan - Iran. World J Gastroenterol. 2005 Jul 14; 11 (26): 4085-9. (Pubitemid 41235607)
25. Mohtasham Amiri Z, Rezvani M, Jafari Shakib R, Jafari Shakib A. Prevalence of hepatitis C virus infection and risk factors of drug using prisoners in Guilan province. East Mediterr Health J. 2007 Mar-Apr; 13 (2): 250-6. (Pubitemid 47045989)
26. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy. 2007 Oct; 18 (5): 359-63. (Pubitemid 47374506)
27. Dalvand S, Agahi C, Spencer C. Drug addicts seeking treatment after the Iranian Revolution: a clinic-based study. Drug Alcohol Depend. 1984 Sep; 14 (1): 87-92. (Pubitemid 14031771)
28. Karimi M, Hashemi A, Ghiam AF, Jahromi SS, Toobaee S. Substance dependency in Iranian patients with hemophilia. Addict Behav. 2007 Feb;32(2):365-9. (Pubitemid 44918208)
29. Estrada AL. Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users. Public Health Rep. 2002; 117 Suppl 1: S126-34.
30. Maier I, Wu GY. Hepatitis C and HIV coinfection: a review. World J Gastroenterol. 2002 Aug; 8 (4): 577-9.
31. Parboosing R, Paruk I, Lalloo UG. Hepatitis C virus seropositivity in a South African Cohort of HIV co-infected, ARV naive patients is associated with renal insufficiency and increased mortality. J Med Virol. 2008 Sep; 80 (9): 1530-6.
32. Devi Kh S, Brajachand N, Singh HL, Singh YM. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users. J Commun Dis. 2005 Mar; 37 (1): 73-7. (Pubitemid 43531943)
33. Shirin T, Ahmed T, Iqbal A, Islam M, Islam MN. Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh. J Health Popul Nutr. 2000 Dec; 18 (3): 145-50.
34. Babudieri S, Longo B, Sarmati L, Starnini G, Dori L, Suligoi B, et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol. 2005 Jul; 76 (3): 311-7.
35. Mojtahedzadeh V, Razani N, Malekinejad M, Vazirian M, Shoaee S, Saberi Zafarghandi MB, et al. Injection drug use in Rural Iran: integrating HIV prevention into iran's rural primary health care system. AIDS Behav. 2008 Jul; 12 (4 Suppl): S7-12.
36. Bart G, Piccolo P, Zhang L, Jacobson I, Schaefer RA, Kreek MJ. Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B. Addiction. 2008 Apr; 103 (4): 681-6. (Pubitemid 351389289)
37. Gerlich M, Gschwend P, Uchtenhagen A, Kramer A, Rehm J. Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002. Eur J Epidemiol. 2006; 21 (7): 545-9.
38. Sabbatani S, Giuliani R, Fulgaro C, Paolillo P, Baldi E, Chiodo F. [HIVAb, HCVAb and HBsAg seroprevalence among inmates of the prison of Bologna and the effect of counselling on the compliance of proposed tests]. Epidemiol Prev. 2004 May-Jun; 28 (3): 163-8.
39. Guyon L, Brochu S, Parent I, Desjardins L. At-risk behaviors with regard to HIV and addiction among women in prison. Women Health. 1999; 29 (3): 49-66. (Pubitemid 29401745)
40. Altaf A, Shah SA, Zaidi NA, Memon A, Nadeem-Ur-Rehman, Wray N. High risk behaviors of injection drug users registered with harm reduction programme in Karachi, Pakistan. Harm Reduct J. 2007; 4: 7.
41. Minola E, Baldo V, Baldovin T, Trivello R, Floreani A. Intrafamilial transmission of hepatitis C virus infection. Eur J Epidemiol. 2006; 21 (4): 293-7. (Pubitemid 43725487)
42. do Sameiro Faria M, Sampaio S, Faria V, Carvalho E. Nephropathy associated with heroin abuse in Caucasian patients. Nephrol Dial Transplant. 2003 Nov; 18 (11): 2308-13.
43. Wurst FM, Dursteler-MacFarland KM, Auwaerter V, Ergovic S, Thon N, Yegles M, et al. Assessment of alcohol use among methadone maintenance patients by direct ethanol metabolites and self-reports. Alcohol Clin Exp Res. 2008 Sep; 32 (9): 1552-7.
44. Weber K, Rockstroh B, Borgelt J, Awiszus B, Popov T, Hoffmann K, et al. Stress load during childhood affects psychopathology in psychiatric patients. BMC Psychiatry. 2008; 8: 63.
45. Pot AM, Melenhorst AS, Onrust S, Bohlmeijer ET. (Cost)effectiveness of life review for older adults: design of a randomized controlled trial. BMC Public Health. 2008; 8: 211. (Pubitemid 351905102)
46. Corcos M, Loas G, Speranza M, Perez- Diaz F, Stephan P, Verrier A, et al. Risk factors for addictive disorders: a discriminant analysis on 374 addicted and 513 nonpsychiatric participants. Psychol Rep. 2008 Apr; 102 (2): 435-49.
47. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician. 2008 Mar; 11 (2 Suppl): S105-20.
48. Faggiano F, Vigna-Taglianti FD, Versino E, Zambon A, Borraccino A, Lemma P. School-based prevention for illicit drugs use: a systematic review. Prev Med. 2008 May; 46 (5): 385-96.
49. Michels, II, Stover H, Gerlach R. Substitution treatment for opioid addicts in Germany. Harm Reduct J. 2007; 4: 5.
50. Small W, Kain S, Laliberte N, Schechter MT, O'Shaughnessy MV, Spittal PM. Incarceration, addiction and harm reduction: inmates experience injecting drugs in prison. Subst Use Misuse. 2005; 40 (6): 831-43. (Pubitemid 40807525)
51. Ramirez-Jonville A. [Drug addiction: harm reduction policies in France and Spain]. Presse Med. 2006 Jul-Aug; 35 (7-8): 1151-61.
52. Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction. 2005 Nov; 100 (11): 1690-700.
53. Wodak A. Harm reduction: Australia as a case study. Bull N Y Acad Med. 1995 Winter; 72 (2): 339-47. (Pubitemid 26127911)
54. McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis. 2005 Jul 1; 41 Suppl 1: S89-95.
55. Novick DM, Kreek MJ. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction. 2008 Jun; 103 (6): 905-18.
56. Sylvestre DL, Zweben JE. Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy. 2007 Oct; 18 (5): 406-10.
57. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007 Sep; 102 (9): 1454-62. (Pubitemid 47246988)
58. Maher L, Li J, Jalaludin B, Wand H, Jayasuriya R, Dixon D, et al. Impact of a reduction in heroin availability on patterns of drug use, risk behaviour and incidence of hepatitis C virus infection in injecting drug users in New South Wales, Australia. Drug Alcohol Depend. 2007 Jul 10; 89 (2-3): 244-50. (Pubitemid 46778789)
59. March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat. 2006 Sep; 31 (2): 203-11.
60. Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995 Jul; 56 (4): 423-32.
61. Loftis JM, Matthews AM, Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs. 2006; 66 (2): 155-74.
62. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007 Oct; 18 (5): 352-8.
63. Sylvestre D. Hepatitis C for addiction professionals. Addict Sci Clin Pract. 2007 Dec; 4 (1): 34-41.